LONDON (ShareCast) - (Sharecast News) - Regenerative medical devices company Tissue Regenix announced on Wednesday that its first delivery of 'OrthoPure XT' has taken place, with additional shipments expected in early 2021.
The AIM-traded firm described OrthoPure XT as a decellularised porcine tendon, developed using its patented 'dCELL' technology.

It was granted CE-mark approval in June for the reconstruction of knee ligaments to restore function and stability.

In August, the company announced its first distribution agreement, focussed on the UK market, with an unnamed speciality supplier of orthopaedic and biologic products.

The group said it had since targeted key European markets, including securing an additional distribution partner in Poland.

Tissue Regenix said it was currently engaged in a number of discussions with potential partners in other geographies.

"Our plan is to establish an initial distribution network for OrthoPure XT and expand as procedural levels return," said chief executive officer Daniel Lee.

"This will be a key product for the Group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market.

"It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020."

At 0946 GMT, shares in Tissue Regenix were down 2.25% at 0.52p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE